The Patent Finder
US

Suspension Formulations of Insulinotropic Peptides and Uses Thereof

US 8,299,025 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Feb 3, 2026 · High confidence

Filed Apr 22, 2008 as application 12/148,896 · Granted Oct 30, 2012
Base term plus 164 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
Term ended Feb 3, 2026
2006 2026
Clock starts
Feb 3, 2006
Term ended
Feb 3, 2026
Granted
Oct 30, 2012
base term after the term ends fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
164
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,114,437, US 8,206,745.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
23
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 164 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Feb 3, 2006, when application 11/347,562, the earliest non-provisional in its chain, was filed (this one was filed Apr 22, 2008)Feb 3, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+164 days, USPTO patent term adjustment recordJul 17, 2026High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 8,114,437, US 8,206,745)capped to Feb 3, 2026High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events3 of 3 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderFeb 3, 2026High confidence

This family

US 8,114,437In force
Aug 2027
Aug 2027
US 8,052,996In force
no later than Feb 2029
no later than Feb 2029
US 8,299,025this patent
Feb 2026
Feb 2026
US 8,211,467Term ended
Feb 2026
Feb 2026
US 8,940,316In force
no later than Jan 2029
no later than Jan 2029
US 8,206,745Term ended
Feb 2026
Feb 2026
US 8,158,150Term ended
Feb 2026
Feb 2026
US 8,273,365Term ended
Feb 2026
Feb 2026
8 of 23 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 12, 2008
Reel 21093, frame 549
Alessi, Thomas R.; Mercer, Ryan D.; Rohloff, Catherine M.; Yang, BingIntarcia Therapeutics, Inc.Assignment of Assignor's Interest
Sep 8, 2010
Reel 24953, frame 525
Intarcia Therapeutics, Inc.Oxford Finance Corporation; Silicon Valley BankSecurity Agreement
Sep 8, 2010
reel/frame not recorded
Intarcia Therapeutics, Inc.Oxford Finance CorporationSecurity Agreement
Sep 8, 2010
reel/frame not recorded
Intarcia Therapeutics, Inc.Silicon Valley BankSecurity Agreement
May 13, 2011
Reel 26279, frame 629
Alessi, Thomas R.; Mercer, Ryan D.; Rohloff, Catherine M.; Yang, BingIntarcia Therapeutics, Inc.Assignment of Assignor's Interest
Sep 23, 2011
Reel 26962, frame 62
Oxford Finance Corporation; Silicon Valley BankIntarcia Therapeutics, Inc.Release of Security Interest
Nov 14, 2012
Reel 29299, frame 678
Intarcia Therapeutics, Inc.U.S. Bank National Association, as Collateral AgentSecurity Agreement
Oct 23, 2015
Reel 36942, frame 544
U.S. Bank National Association, as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Oct 9, 2019
Reel 50673, frame 20
Intarcia Therapeutics, Inc.; Intarcia Ireland LimitedMidcap Financial Trust, As AgentSecurity Interest
Oct 23, 2019
Reel 50801, frame 267
Intarcia Therapeutics, Inc.Baupost Private Investments Bviv-3, L.L.C., as Collateral AgentSecurity Interest
Jan 29, 2020
Reel 51739, frame 453
Baupost Private Investments Bviv-3, L.L.C. as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
Reel 52433, frame 1
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.; Intarcia Ireland LimitedRelease of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Ireland LimitedRelease of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited